Denali Therapeutics’ (DNLI) Outperform Rating Reiterated at William Blair

Denali Therapeutics (NASDAQ:DNLI)‘s stock had its “outperform” rating reiterated by investment analysts at William Blair in a note issued to investors on Friday,RTT News reports.

DNLI has been the topic of a number of other reports. The Goldman Sachs Group decreased their price objective on shares of Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Deutsche Bank Aktiengesellschaft started coverage on Denali Therapeutics in a research note on Tuesday, February 11th. They set a “buy” rating and a $31.00 price objective for the company. HC Wainwright increased their price target on Denali Therapeutics from $80.00 to $87.00 and gave the stock a “buy” rating in a report on Friday. Robert W. Baird started coverage on shares of Denali Therapeutics in a research note on Tuesday, January 7th. They issued an “outperform” rating and a $31.00 target price for the company. Finally, Stifel Nicolaus upgraded shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a report on Monday, December 16th. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $37.42.

Denali Therapeutics Stock Performance

Shares of Denali Therapeutics stock traded down $1.43 during trading on Friday, reaching $17.17. The company’s stock had a trading volume of 622,880 shares, compared to its average volume of 934,075. Denali Therapeutics has a one year low of $14.56 and a one year high of $33.33. The firm has a market cap of $2.47 billion, a price-to-earnings ratio of -6.22 and a beta of 1.43. The business’s fifty day moving average price is $21.38 and its 200-day moving average price is $24.59.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.08. Sell-side analysts anticipate that Denali Therapeutics will post -2.71 EPS for the current year.

Insider Buying and Selling at Denali Therapeutics

In other news, insider Carole Ho sold 12,255 shares of Denali Therapeutics stock in a transaction on Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $247,796.10. Following the completion of the sale, the insider now owns 178,580 shares of the company’s stock, valued at approximately $3,610,887.60. This trade represents a 6.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Vicki L. Sato sold 3,080 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the sale, the director now directly owns 107,976 shares of the company’s stock, valued at $2,257,778.16. This represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 47,940 shares of company stock valued at $973,442 in the last quarter. 7.90% of the stock is currently owned by insiders.

Institutional Trading of Denali Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in DNLI. Sterling Capital Management LLC raised its holdings in shares of Denali Therapeutics by 589.9% during the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company’s stock worth $36,000 after buying an additional 1,516 shares in the last quarter. Quest Partners LLC acquired a new position in Denali Therapeutics in the 3rd quarter valued at approximately $73,000. GF Fund Management CO. LTD. bought a new position in Denali Therapeutics during the 4th quarter worth $62,000. Point72 Hong Kong Ltd bought a new position in shares of Denali Therapeutics during the fourth quarter worth about $65,000. Finally, PNC Financial Services Group Inc. boosted its stake in shares of Denali Therapeutics by 30.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock valued at $77,000 after purchasing an additional 885 shares during the last quarter. Institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.